deListed Australia
 
SEARCH LISTED OR DELISTED COMPANY
Any AUS or NZ company

Browse Australian delisted companies

0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Browse terminated Australian managed funds

0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
SEARCH PRIVATE COMPANY
SEARCH FUNDS

Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:

TBG DIAGNOSTICS LIMITED (ASX.TDL)

ASX Announcements (courtesy of ASX)

201620172018201920202021

ASX, Legal & CGT Status

SHARE PRICES

(updated at weekends)
Former (or subsequent) names
CompanyFROMTO
TBG DIAGNOSTICS LIMITED02/02/2016
PROGEN PHARMACEUTICALS LIMITED02/04/200702/02/2016
PROGEN INDUSTRIES LIMITED02/04/2007
Shareholder links
Our website ranking of TDL: rating 1
(1 out of 5)
COMPANY WEBSITE:

 

REGISTRY:
Computershare Brisbane
Level 1, 200 Mary Street Brisbane QLD 4000
Tel : +61 (0)3 9415 4000 or 1300 850 505 (within Australia)
Fax : +61 7 3229 9860
RegistryWebsite RegistryEmail

Company details
ISIN: AU000000TDL4
Address: Level 18, 101 Collins Street Melbourne VIC 3000 Australia
Tel:  07 3088 7926 Fax:  07 3394 4394

Date first listed: 22/12/1995

Sector: Pharmaceuticals & Biotechnology
Industry Group: XHJ
Activities: Research & development of potential biopharmaceutical therapeutics for the treatement of human diseases; development, manufacture, importation & distribution of a range of molecular biology products, consumables & fine chemicals for the scientific researc

Shareholders in this company should consider crystallising a capital loss in 2024/25 by selling their shares. This process is now much easier and quicker. It can be achieved online by entering transaction details here. While, this usually makes good economic sense we recommend you seek professional advice before buying or selling securities, your accountant is probably the best person.

10/07/2024

delisted following failure to pay the annual ASX listing fees per Listing Rule 17.15

30/08/2021

we understand the company failed to pay to ASX Limited the annual listing fees for the year ending 30 June 2022

30/08/2021

The company has failed to pay to ASX Limited the annual listing fees for the year ending 30 June 2022, and the entity's securities are already suspended from quotation.

23/08/2021

The company lodges its Quarterly Activities/Appendix 4C Cash Flow Report.

03/08/2021

The company releases the results of its meeting.

29/07/2021

The company releases a Restatement of its FY2020 Financial Statements.

29/07/2021

The company releases its Annual General Meeting Letter to Shareholders.

25/06/2021

The company's 2020 AGM will be held at 1:00 pm (AEST) 29 July 2021 via a virtual meeting.

25/06/2021

TBG Diagnostics Limited has entered into an agreement for the sale of shares held by the Company in its subsidiary company, TBG Inc. with Dong Yuan Hua Xin (Beijing) Capital Management Limited Company. The Company is selling approximately 5% of TBG Inc to Dong Yuan under this transaction. Following completion of the Company's sale of 5% of TBG Inc to Dong Yuan pursuant to the Agreement, the Company will hold a 41.25% shareholding and Dong Yuan will hold a 38.71% shareholding in TBG Inc.

07/06/2021

The company will hold its AGM on 29 July 2021. The time and other details relating to the meeting will be advised in the notice of meeting to be sent in due course. The period for nomination of directors will close on 10 June 2021.

20/05/2021

The company lodges its Quarterly Activities Report and Appendix 4C.

03/05/2021

The company releases an Appendix 4G.

31/03/2021

The company lodges its Annual Report to shareholders.

31/03/2021

The company lodges its Full Year Statutory Accounts.

31/03/2021

On 12 March 2021, ASIC made a determination restricting TBG Diagnostics Limited from relying on the exceptions in sectin 713 to use transactino-specific disclosure until 11 March 2022. This restriction means that the company will not be able to rely on the reduced disclosure rules under section 713 and instead must issue a full prospectus in order to raise funds from certain investors. The restriction will not affect the operation and business of TDL.

18/03/2021

The company issues a Response to ASX Query Letter.

03/03/2021

The company lodges its Preliminary Final Report.

26/02/2021

The company lodges its Quarterly Activities Report and Appendix 4C.

01/02/2021

The company releases its Securities Trading Policy.

20/11/2020

The company's investee company, TBG Biotechnology XIamen, has received the CE Mark approval for its SARS-CoV-2 Antigen Rapid Test.

11/11/2020

The company lodges its Quarterly Activities Report.

02/11/2020

The company lodges its Appendix 4C - quarterly.

02/11/2020

The company's wholly owned subsisiary, TBG Biotechnology Corp., entered into a distribution agreement with Medigen Biotechnology Corp. on 15 February 2020 to distribute TBG Taiwan's SARS-CoV-2 related diagnostic products, including Rapid Test Kit and Nucleic Acid Test Kit. The Distribution Agreement has expanded Medigen's existing exclusive distribution right granted under the distribution contract previously entered into between TBG Taiwan and Medigen in January 2015 to include the Test Kits. This provides an ability for expansion of the business of manufacturing and distributing the Test Kits through the distribution expertise and network of Medigen.

21/09/2020

The company's wholly owned subsidiary, TBG Biotechnology Corp., has received an Emergency Use Authorisation from the U.S. FDA for its TBG SARS-CoV-2 IgG / IgM Rapid Test Kit.

02/09/2020

The company lodges its Half Yearly Report and Accounts.

31/08/2020

The company lodges its Quarterly Activities Report.

31/07/2020

The company lodges its Appendix 4C - quarterly.

31/07/2020

The company releases the Results of its Meeting.

31/07/2020

TBG Diagnostics Limited's wholly owned subsidiary, TBG Biotechnology Corp., has received an emergency use authorisation from the Taiwan Ministry of Health and Welfare for its ExProbe SARS-CoV-2 Testing Kit.

29/07/2020

The company's 2019 AGM will be held at 12:30 pm (AEST) 31 July 2020 at Boardroom, Level 27 101 Collins Street Melbourne VIC.

26/06/2020

The company releases an Appendix 4G.

15/06/2020

The company lodges its Annual Report to shareholders.

15/06/2020

The company lodges its Full Year Statutory Accounts.

12/06/2020

TBG Biotechnology Corp. has received an Emergency Use Authorisation from the United States Food and Drug Administration for its ExProbe SARS-CoV-2 Testing Kit.

12/06/2020

The company will hold its AGM on 31 July 2020. The time and other details relating to the meeting will be advised in the Notice of Meeting to be sent in due course. The period for nomination of Directors will close on 18 June 2020.

11/06/2020

The company's wholly owned subsidiary, TBG Biotechnology Corp., has received the CE Mark approval for its ExProbe SARS-CoV-2 Testing Kit and SARS-CoV-2 IgG / IgM Rapid Test Kit.

21/05/2020

The company has received notification from TBG Biotechnology Xiamen Inc. that the Chinese Department of Commerce has lifted the bans restricting the exportation of TBG Xiamen's CE Marked COVID-19 Nucleic Acid Test Kits. Following the lift of the export ban the COVID-19 Nucleic Acid Test Kits are now able to be exported from China for sale throughout the European Economic Area subject to individual countries accepting import of the test kit. The company has a 46.65% interest in the equity of TBG Xiamen.

05/05/2020

The company issues a Response to ASX Query Letter.

15/04/2020

TBG Xiamen's COVID-19 Virus Diagnostic Kits do not currently have China medical device product registration certification required under the new export requirements as recently announced by the Chinese Government, therefore TBG Xiamen are currently unable to sell and export their COVID-19 Nucleic Acid Diagnostics Kits from China. Without the China medical device product registration certification, TBG Xiamen is also currently unable to sell their COVID19 Nucleic Acid Diagnostics Kits within China. While TBG Xiamen has received interest from several buyers, in light of these new restrictions no COVID-19 Nucleic Acid Diagnostics Kits will be exported or sold while these restrictions remain in place or until TBG Xiamen receives the required certifications for sale and export.

06/04/2020

The securities of TBG Diagnostics Limited will be suspended from quotation immediately under Listing Rule 17.3, pending further enquires by ASX. The securities will remain suspended until further notice.

19/03/2020

The securities of TBG Diagnostics Limited (the "Company") will be reinstated to official quotation from the commencement of trading on Wednesday, 3 February 2016, following the Company's compliance with listing rule 11.1.3 and Chapters 1 and 2 of the ASX Listing Rules. Security Code: TDL

02/02/2016

name changed from Progen Pharmaceuticals Limited

02/02/2016
View ASX Announcements (courtesy of ASX)

 

Click here for free access to this company's:
ASX, Legal & CGT Status

Your comments

Please read our Terms before viewing comments.

 

Company Updates
Post your comments here
Please read our Terms before posting comments.
OMISSIONS
    You can post a comment here about this company

    Please click in the "I'm not a robot" box. If an image appears, enter the word/figures you see in the image.

    loading Posting your comments. Please wait...

    Directors' on-market share transactions (last 5)

    rss feeds

    Purchases Sales

    DATEDIRECTORNATURENUMBERPRICEAMOUNT
    11/01/2016Stanley ChangOn market500,000$0.210$105,000
    14/05/2014Jitto ArulampalamOn market40,000$1.010$40,398
    12/03/2014Heng TangOn market10,000$0.520$5,200
    12/12/2013Heng TangOn market10,000$0.220$2,196
    06/12/2013Heng TangOn market33,000$0.227$7,475

    Click here for the last 20 transactions all companies

    Directors & Executives (current)
    NAMETITLEDATE OF APPT
    Jitto ArulampalamExecutive Chairman12/06/2013
    Willy HsuCOO01/02/2019
    Emily LeeNon Exec Director07/12/2015
    Bing-Cheng LiuNon Exec Director22/03/2021
    Stanley ChangNon Exec Director07/12/2015
    Justyn StedwelCompany Secretary

    Date of first appointment, title may have changed.

    Directors & Executives (former)
    NAMETITLEDATE OF APPOINTMENTDATE OF RESIGNATION
    Hsi-Kai WangNon Exec Director28/05/201822/03/2021
    Eugene ChengNon Exec Director07/12/201528/05/2019
    Edward ChangNon Exec Director03/02/201628/05/2018
    Christopher HarveyIndependent Director16/03/201507/12/2015
    Hongjen ChangNon Exec Director29/11/201307/12/2015
    Heng TangManaging Director, CEO17/07/200916/03/2015
    Stuart JamesNon Exec Chairman01/07/200928/11/2013
    Woei-Jia JiangDirector16/06/201112/07/2013
    Paul DixonCFO03/04/200912/10/2012
    Thomas BurtNon Exec Director17/07/200930/11/2011
    Sue MacLemanCEO06/04/201026/08/2011

    Date of first appointment, title may have changed.